Comment
Author: Admin | 2025-04-28
And nervousness were reported in 0.1% to 1.9% of patients taking celecoxib (the active ingredient contained in Celebrex) 100 to 200 mg twice a day or 200 mg once a day.[Ref]OcularUncommon (0.1% to 1%): Vitreous floaters, conjunctival hemorrhageFrequency not reported: Blurred vision, cataract, conjunctivitis, eye pain, glaucoma[Ref]Blurred vision, cataract, conjunctivitis, eye pain, and glaucoma were reported in 0.1% to 1.9% of patients taking celecoxib (the active ingredient contained in Celebrex) 100 to 200 mg twice a day or 200 mg once a day. In the long-term polyp prevention studies in which exposure to celecoxib was 400 to 800 mg per day for up to 3 years, vitreous floaters or conjunctival hemorrhage was reported in at least 0.1% of patients to less than 1% of patients.[Ref]MusculoskeletalUncommon (0.1% to 1%): Epicondylitis, tendon ruptureFrequency not reported: Arthralgia, arthrosis, bone disorder, accidental fracture, myalgia, neck stiffness, synovitis, tendinitis[Ref]Arthralgia, arthrosis, bone disorder, accidental fracture, myalgia, neck stiffness, synovitis, and tendinitis were reported in 0.1% to 1.9% of patients taking celecoxib (the active ingredient contained in Celebrex) 100 to 200 mg twice a day or 200 mg once a day. In the long-term polyp prevention studies in which exposure to celecoxib was 400 to 800 mg per day for up to 3 years, epicondylitis or tendon rupture were reported in at least 0.1% of patients to less than 1% of patients.[Ref]OtherFrequency not reported: Asthenia fatigue, fever, hot flushes, cyst, painPostmarketing reports: Conjunctivitis[Ref]Asthenia fatigue, fever, hot flushes, influenza-like illness, cyst, and pain were reported in 0.1% to 1.9% of patients taking celecoxib 100 to 200 mg twice a day or 200 mg once a day.[Ref]ImmunologicRare (less than 0.1%): Gangrene Frequency not reported: Herpes simplex, herpes zoster, bacterial infection, fungal infection, soft tissue infection, viral infection, moniliasis, moniliasis genital, influenza-like illnessPostmarketing reports: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), sepsis[Ref]Herpes simplex, herpes zoster, bacterial infection, fungal infection, soft tissue infection, viral infection, moniliasis, moniliasis genital, and influenza-like illness were reported in 0.1% to 1.9% of patients taking celecoxib 100 to 200 mg twice a day or 200 mg once a day.[Ref]OncologicFrequency not reported: Breast fibroadenosis, breast neoplasm[Ref]Breast fibroadenosis and breast neoplasm were reported in 0.1% to 1.9% of patients taking celecoxib 100 to 200 mg twice a day or 200 mg once a day.[Ref]HypersensitivityFrequency not reported: Hypersensitivity Postmarketing reports: Anaphylactic shock, anaphylactic reaction, angioedema[Ref]Hypersensitivity was reported in 0.1% to 1.9% of patients taking celecoxib (the active ingredient contained in Celebrex) 100 to 200 mg twice a day or 200 mg once a day.[Ref]MetabolicUncommon (0.1% to 1%): HyperkalemiaFrequency not reported: Increased blood urea nitrogen, increased creatinine phosphokinase, diabetes mellitus, hypercholesterolemia, hyperglycemia, hypokalemia, non-protein nitrogen increased, creatinine increased, alkaline phosphatase increased, weight increased, anorexiaPostmarketing reports: Hypoglycemia, hyponatremia[Ref]Increased blood urea nitrogen, increased creatinine phosphokinase, diabetes mellitus, hypercholesterolemia, hyperglycemia, hypokalemia, non-protein nitrogen increased, creatinine increased, alkaline phosphatase increased, anorexia, and increased weight increase were reported in 0.1% to 1.9% of patients taking celecoxib 100 to 200 mg twice a day or 200 mg once a day.[Ref]OtherUncommon (0.1% to 1%): LabyrinthitisVery rare
Add Comment